神经退行性疾病中的转谷氨酰胺酶激活
Transglutaminase activation in neurodegenerative diseases.
作者信息
Jeitner Thomas M, Muma Nancy A, Battaile Kevin P, Cooper Arthur Jl
机构信息
Applied Bench Core, Winthrop University Hospital, 222 Station Plaza North, Suite 502, Mineola, NY 11501, USA Tel.: +1 516 663 3455
出版信息
Future Neurol. 2009 Jul 1;4(4):449-467. doi: 10.2217/fnl.09.17.
Abstract
The following review examines the role of calcium in promoting the in vitro and in vivo activation of transglutaminases in neurodegenerative disorders. Diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease exhibit increased transglutaminase activity and rises in intracellular calcium concentrations, which may be related. The aberrant activation of transglutaminase by calcium is thought to give rise to a variety of pathological moieties in these diseases, and the inhibition has been shown to have therapeutic benefit in animal and cellular models of neurodegeneration. Given the potential clinical relevance of transglutaminase inhibitors, we have also reviewed the recent development of such compounds.
摘要
以下综述探讨了钙在促进神经退行性疾病中谷氨酰胺转移酶的体外和体内激活方面的作用。诸如阿尔茨海默病、帕金森病和亨廷顿病等疾病表现出谷氨酰胺转移酶活性增加以及细胞内钙浓度升高，这两者可能存在关联。钙对谷氨酰胺转移酶的异常激活被认为会在这些疾病中产生多种病理成分，并且在神经退行性变的动物和细胞模型中，抑制作用已显示出具有治疗益处。鉴于谷氨酰胺转移酶抑制剂潜在的临床相关性，我们还综述了此类化合物的最新进展。
相似文献
1
Transglutaminase activation in neurodegenerative diseases.
Future Neurol. 2009 Jul 1;4(4):449-467. doi: 10.2217/fnl.09.17.
2
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Int J Alzheimers Dis. 2011 Feb 16;2011:865432. doi: 10.4061/2011/865432.
3
Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
Amino Acids. 2010 Feb;38(2):653-8. doi: 10.1007/s00726-009-0428-3. Epub 2009 Dec 5.
4
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Amino Acids. 2013 Jan;44(1):111-8. doi: 10.1007/s00726-011-1081-1. Epub 2011 Sep 22.
5
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2013 Aug;8(2):161-8. doi: 10.2174/15748898113089990001.
6
Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
Int J Mol Sci. 2024 Feb 17;25(4):2364. doi: 10.3390/ijms25042364.
7
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2010 Nov;5(3):195-202. doi: 10.2174/157488910793362430.
8
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2013 Dec;8(3):235-42. doi: 10.2174/1574889808666131128105630.
9
Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2014;9(2):101-9. doi: 10.2174/1574889809666140613114850.
10
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Recent Pat CNS Drug Discov. 2014;9(2):76-84. doi: 10.2174/1574889809666141111160124.
引用本文的文献
1
The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.
Int J Mol Sci. 2024 Dec 14;25(24):13424. doi: 10.3390/ijms252413424.
2
Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
Int J Mol Sci. 2024 Feb 17;25(4):2364. doi: 10.3390/ijms25042364.
3
Oxidative stress and neuroimmune proteins in a mouse model of autism.
Cell Stress Chaperones. 2023 Mar;28(2):201-217. doi: 10.1007/s12192-023-01331-2. Epub 2023 Feb 16.
4
Calmodulin Binding Domains in Critical Risk Proteins Involved in Neurodegeneration.
Curr Issues Mol Biol. 2022 Nov 21;44(11):5802-5814. doi: 10.3390/cimb44110394.
5
Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing.
FEBS Open Bio. 2020 Apr;10(4):495-506. doi: 10.1002/2211-5463.12826. Epub 2020 Mar 16.
6
Cystamine and cysteamine as inhibitors of transglutaminase activity .
Biosci Rep. 2018 Sep 5;38(5). doi: 10.1042/BSR20180691. Print 2018 Oct 31.
7
Microglia Endocytose Amyloid β Through the Binding of Transglutaminase 2 and Milk Fat Globule EGF Factor 8 Protein.
Neurochem Res. 2018 Jan;43(1):41-49. doi: 10.1007/s11064-017-2284-y. Epub 2017 May 3.
8
Transglutaminases Derived from Astrocytes Accelerate Amyloid β Aggregation.
Neurochem Res. 2017 Aug;42(8):2384-2391. doi: 10.1007/s11064-017-2258-0. Epub 2017 Apr 9.
9
The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.
J Biol Chem. 2016 Apr 22;291(17):9119-32. doi: 10.1074/jbc.M115.699108. Epub 2016 Feb 18.
10
Critical Evaluation of the Changes in Glutamine Synthetase Activity in Models of Cerebral Stroke.
Neurochem Res. 2015 Dec;40(12):2544-56. doi: 10.1007/s11064-015-1667-1. Epub 2015 Aug 2.
本文引用的文献
1
Transglutaminases and neurodegeneration.
J Neurochem. 2009 May;109 Suppl 1(Suppl 1):160-6. doi: 10.1111/j.1471-4159.2009.05843.x.
2
Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.
Brain Pathol. 2010 Jan;20(1):176-89. doi: 10.1111/j.1750-3639.2008.00258.x. Epub 2009 Mar 10.
3
The Parkinson chimera.
Neurology. 2009 Feb 17;72(7 Suppl):S2-11. doi: 10.1212/WNL.0b013e318198daec.
4
Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells.
J Biol Chem. 2009 Apr 10;284(15):10211-22. doi: 10.1074/jbc.M809671200. Epub 2009 Feb 9.
5
Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.
J Biol Chem. 2009 May 8;284(19):13128-42. doi: 10.1074/jbc.M809067200. Epub 2009 Jan 21.
6
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
J Biol Chem. 2009 Apr 24;284(17):11048-58. doi: 10.1074/jbc.M806559200. Epub 2009 Jan 13.
7
Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease.
J Biol Chem. 2009 Mar 6;284(10):6554-65. doi: 10.1074/jbc.M807746200. Epub 2008 Dec 11.
8
Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration.
J Biol Chem. 2009 Mar 6;284(10):6566-74. doi: 10.1074/jbc.M808277200. Epub 2008 Dec 11.
9
Alpha-synuclein misfolding and neurodegenerative diseases.
Curr Protein Pept Sci. 2008 Oct;9(5):507-40. doi: 10.2174/138920308785915218.
10
Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.
Ann Neurol. 2008 Sep;64(3):332-43. doi: 10.1002/ana.21450.
Zotero 插件